Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropsychopharmacology ; 39(10): 2275-87, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24910347

ABSTRACT

Anesthesia in infancy impairs performance in recognition memory tasks in mammalian animals, but it is unknown if this occurs in humans. Successful recognition can be based on stimulus familiarity or recollection of event details. Several brain structures involved in recollection are affected by anesthesia-induced neurodegeneration in animals. Therefore, we hypothesized that anesthesia in infancy impairs recollection later in life in humans and rats. Twenty eight children ages 6-11 who had undergone a procedure requiring general anesthesia before age 1 were compared with 28 age- and gender-matched children who had not undergone anesthesia. Recollection and familiarity were assessed in an object recognition memory test using receiver operator characteristic analysis. In addition, IQ and Child Behavior Checklist scores were assessed. In parallel, thirty three 7-day-old rats were randomized to receive anesthesia or sham anesthesia. Over 10 months, recollection and familiarity were assessed using an odor recognition test. We found that anesthetized children had significantly lower recollection scores and were impaired at recollecting associative information compared with controls. Familiarity, IQ, and Child Behavior Checklist scores were not different between groups. In rats, anesthetized subjects had significantly lower recollection scores than controls while familiarity was unaffected. Rats that had undergone tissue injury during anesthesia had similar recollection indices as rats that had been anesthetized without tissue injury. These findings suggest that general anesthesia in infancy impairs recollection later in life in humans and rats. In rats, this effect is independent of underlying disease or tissue injury.


Subject(s)
Anesthesia, General/adverse effects , Memory, Long-Term/drug effects , Recognition, Psychology/drug effects , Animals , Association Learning/drug effects , Brain/drug effects , Brain/growth & development , Child , Female , Humans , Intelligence Tests , Male , Mental Recall/drug effects , Methyl Ethers/adverse effects , Neuropsychological Tests , Olfactory Perception/drug effects , ROC Curve , Random Allocation , Rats, Sprague-Dawley , Sevoflurane
2.
Breast Cancer Res Treat ; 82(3): 169-83, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14703064

ABSTRACT

Many tumor-associated antigens (TAAs) represent 'self' antigens and as such, are subject to the constraints of immunologic tolerance. There are significant barriers to eliciting anti-tumor immune responses of sufficient magnitude. We have taken advantage of a Venezuelan equine encephalitis-derived alphavirus replicon vector system with documented in vivo tropism for immune system dendritic cells. We have overcome the intrinsic tolerance to the 'self' TAA rat neu and elicited an effective anti-tumor immune response using this alphavirus replicon vector system and a designed target antigen in a rigorous rat mammary tumor model. We have demonstrated the capacity to generate 50% protection in tumor challenge experiments (p = 0.004) and we have confirmed the establishment of immunologic memory by both second tumor challenge and Winn Assay (p = 0.009). Minor antibody responses were identified and supported the establishment of T helper type 1 (Th1) anti-tumor immune responses by isotype. Animals surviving in excess of 300 days with established effective anti-tumor immunity showed no signs of autoimmune phenomena. Together these experiments support the establishment of T lymphocyte dependent, Th1-biased anti-tumor immune responses to a non-mutated 'self' TAA in an aggressive tumor model. Importantly, this tumor model is subject to the constraints of immunologic tolerance present in animals with normal developmental, temporal, and anatomical expression of a non-mutated TAA. These data support the continued development and potential clinical application of this alphaviral replicon vector system and the use of appropriately designed target antigen sequences for anti-tumor immunotherapy.


Subject(s)
Antigens, Neoplasm/immunology , Disease Models, Animal , Encephalitis Virus, Venezuelan Equine/genetics , Mammary Neoplasms, Experimental/immunology , Replicon/immunology , Vaccines, Synthetic/immunology , Amino Acid Sequence , Animals , Female , Genetic Vectors/immunology , Genetic Vectors/therapeutic use , Humans , Immunization , Mammary Neoplasms, Experimental/therapy , Molecular Sequence Data , Neoplasm Proteins/immunology , Rats , Rats, Inbred F344 , Receptor, ErbB-2/chemistry , Receptor, ErbB-2/genetics , Receptor, ErbB-2/immunology , Self Tolerance
SELECTION OF CITATIONS
SEARCH DETAIL
...